This activity provides an illustrative view of the natural history of AMD and risk of progression to neovascular AMD (nAMD). Faculty review the clinical imaging approaches used to monitor disease progression during treatment with more durable anti-VEGF therapies, with a focus on clinical trials versus clinical practice and how to effectively extend dosing intervals.